Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Simply provide your insurance information, and our team will handle the rest, ensuring you have the information you need to make decisions about your treatment
Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments [11]
Visit us online
Dosing typically follows the same 10 g/kg or 10 ng/kg intraperitoneal once-daily pattern used in tendon work
